Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Watchlisten für Ihre Werte
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

Business Leaders

Aktuelle NewsUnternehmenMärkteWirtschaft & ForexRohstoffeZinssätzeBusiness LeadersInstitutionelle AnlegerTermineSektoren 
HomeAlle NewsMeistgelesene ArtikelBusiness Leaders Biografien
Übersicht 
Mr. Daniel E. Geffken is a Chief Financial Officer at Eloxx Pharmaceuticals, Inc., a Chief Financial Officer at CalciMedica, Inc., a Chief Financial Officer at DermBiont, Inc., a Chief Financial Officer at Locust Walk Acquisition Corp., a Chief Financial Officer at Palvella Therapeutics, Inc., a Chief Financial Officer at Privo Technologies, Inc., an Independent Director at Windtree Therapeutics, Inc., a Chief Financial Officer at Apic Bio, Inc., a Chief Financial Officer at Vigeo Therapeutics, Inc., a Chief Financial Officer at ProMIS Neurosciences, Inc., a Chief Financial Officer at Antolrx, Inc., a Chief Financial Officer & Director at Elicio Therapeutics, Inc., a Co-Managing Director at Danforth Advisors LLC, a Chief Financial Officer at Artax Biopharma, Inc., a Chief Financial Officer at Clear Creek Bio, Inc., a Chief Financial Officer at GenePeeks, Inc., a Chief Financial Officer at Matrivax Research & Development Corp., a Chief Financial Officer at Nemucore Medical Innovations, Inc., a Chief Financial Officer at Prilenia Therapeutics Development Ltd., a Chief Financial Officer at United Neuroscience Ltd., a Chief Financial Officer at Vaxxinity, Inc. and a Chief Financial Officer at Windgap Medical, Inc.

He is on the Board of Directors at Windtree Therapeutics, Inc., Elicio Therapeutics, Inc. and SG DAN Holdings LLC.

He received his undergraduate degree from The Wharton School of the University of Pennsylvania and an MBA from Harvard Business School.


Aktuelle Stellungen und Verantwortungsbereiche Daniel E. Geffken 
NameTitel Seit
Vaxxinity, Inc.
(Biotechnologie)
Chief Financial Officer -
Phoenix Biotech Acquisition Corp.
(Holdinggesellschaften)
Chief Financial Officer 2021
ProMIS Neurosciences, Inc.
(Biotechnologie)
Chief Financial Officer 2017
Windtree Therapeutics, Inc.
(Biotechnologie)
Independent Director 2019
OPY Acquisition Corp. I
(Holdinggesellschaften)
CFO, Principal Financial & Accounting Officer 2021
Eloxx Pharmaceuticals, Inc.
(Biotechnologie)
Chief Financial & Accounting Officer 2021
Palvella Therapeutics, Inc. Chief Financial Officer 2020
Matrivax Research & Development Corp. Chief Financial Officer -
Myeloid Therapeutics, Inc. Chief Financial Officer -
Prilenia Therapeutics Development Ltd. Chief Financial Officer -
Privo Technologies, Inc. Chief Financial Officer 2020
Apic Bio, Inc. Chief Financial Officer 2018
Clear Creek Bio, Inc. Chief Financial Officer -
DermBiont, Inc. Chief Financial Officer 2020
Antolrx, Inc. Chief Financial Officer 2016
United Neuroscience Ltd. Chief Financial Officer -
Vigeo Therapeutics, Inc. Chief Financial Officer 2017
GenePeeks, Inc. Chief Financial Officer -
Nemucore Medical Innovations, Inc. Chief Financial Officer -
Windgap Medical, Inc. Chief Financial Officer -
Artax Biopharma, Inc. Chief Financial Officer -
CalciMedica, Inc. Chief Financial Officer 2020
SG DAN Holdings LLC Director -
Elicio Therapeutics, Inc. Chief Financial Officer & Director 2014
Danforth Advisors LLC Co-Managing Director 2011


Anteile an Daniel E. Geffken 
NameAktien%Wert
Eloxx Pharmaceuticals, Inc. (ELOX)
(Biotechnologie)
50 0000,058%35 300 USD
Windtree Therapeutics, Inc. (WINT)
(Biotechnologie)
2 0690,0073%3 321 USD
ProMIS Neurosciences, Inc. (PMN)
(Biotechnologie)
00,0000%0 USD
Graybug Vision, Inc. (GRAY)
(Biotechnologie)
00,0000%0 USD
Atea Pharmaceuticals, Inc. (AVIR)
(Biotechnologie)
00,0000%0 USD


Daniel E. Geffken: Persönliches Netzwerk 
Meistgelesene News 
18.01.ELON MUSK : Telsa-Investoren drängen Richter, Musk zur Rückzahlung von 13 Mrd. Dollar für SolarCity-Deal anzuweisen
MR
14.01.JACK DORSEY : Jack Dorseys Block will ein offenes Bitcoin-Schürfsystem aufbauen
MR
14.01.ELON MUSK : Tesla-Waren können mit Dogecoin gekauft werden, sagt Musk in einem Tweet
MR
20.01.ALAN JOPE : Unilever-Aktien steigen nach der Entscheidung, das Angebot für GSK-Vermögenswerte nicht zu erhöhen
MR
24.01.NELSON PELTZ : Insider - Hedgefonds-Manager Peltz nimmt sich Unilever vor
RE
25.01.JOHN HESS : Hess erhöht Produktionskapitalbudget um 37%
MR
19.01.HAL BARRON : GSK-Chefwissenschaftler Barron wechselt zu US-Biotech-Start-up
MR
12.01.GORDON RISKE : Mit neuem Chef ins neue Jahr
DP
13.01.Australisches Unternehmen Crown erhält höheres Übernahmeangebot von Blackstone
MR
17.01.MARKUS KREBBER : Deutschland wird Energieimportland bleiben
DP
Weitere Nachrichten und Newsletter


© 2022 People and Ownership :   
Daniel E. Geffken : Verbindungen